Merck’s Keytruda Reduces Bladder Cancer Risk by 31% (NYSE:MRK)

Merck fails to collect required revenue

Erik S. Lesser/Getty Images News

Merck (NYSE:MRK) announced detailed results from the Phase 3 AMBASSADOR trial on Friday, noting that its anti-PD1 therapy Keytruda reduced the risk of disease recurrence or death by 31% after surgery in patients with urothelial carcinoma, a form of cancer of the bladder.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *